Clinical and pharmacoeconomic aspects of anti-TNF therapy change for medical reasons
Abstract
The substitution of one drug for another within one class can be caused by both medical indications, such as low therapeutic efficacy, and by non-medical factors, for example, by choosing a less expensive drug. In this article, the available data on the impact of non-medical switching on the clinical and pharmacoeconomic indices of anti-TNF therapy with drugs are considered.
About the Authors
U. S. Gushchina
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
S. K. Zyryanov
Peoples' Friendship University of Russia, Moscow, Russia
Russian Federation
Russian Federation
I. A. Orlikhina
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
References
1. H-125.991 Drug Formularies and Therapeutic Interchange. Chicago,IL: American Medical Association, 2016. Available at: https://www.amaassn.org/ [Last accessed 15 December 2015].
2. Gray T., Bertch K., Galt K., et al. ACCP position statement: guidelines for therapeutic interchange - 2004, Pharmacotherapy. 2005; 25: 1666-80.
3. Saseen J.J., Ghushcyan V., Kaila S., et al. Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers. J ClinHypertens. 2013; 15: 888-924.
4. Gates R., Cookson T., Ito M., et al. Therapeutic conversion from fosinopril to benazepril at a Veterans Affairs medical center. Am J Health-Syst Pharm. 2006; 63: 1066-8.
5. Billups S.J., Plushner S.L., Olson K.L., et al. Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization. J Manag Care Pharm. 2005; 11: 681.
6. Graham M.R., Allcock N.M. Irbesartan substitution for valsartan or losartan in treating hypertension. Ann Pharmacother. 2002; 36: 1840-4.
7. Taylor A.J., Grace K., Swiecki J., et al. Lipid-lowering efficacy, safety and costs of a large-scale therapeutic statin formulary conversion program. Pharmacotherapy. 2001; 21: 1130-9.
8. Good C.B., Fultz S.L., Trilli L., Etchason J. Therapeutic substitution of cimetidine for nizatidine was not associated with an increase in healthcare utilization. Am J Manag Care. 2000; 6: 1141-6.
9. Schachtner J.M., Guharoy R., Medicis J.J., et al. Prevalence and cost savings of therapeutic interchange among U.S. hospitals. Am J Health-Syst Pharm. 2005; 59: 529-33.
10. Chu R., Torstensson D., Pugatch M. Patient safety and comfort: the challenges of switching medicines. London, UK: Stockholm Network, 2010. Available at: http://www.patients-rights.org/upload images/Patient_Safety_and_Comfort_The_Challenges_of_Switching.pdf [Last accessed 8 December 2015].
11. Cote B.R., Petersen E.A. Impact of therapeutic switching in long-term care. Am J Manag Care 2008;14:SP23-8
12. Global Alliance for Patient Access: NOR-SWITCH: What will Norway’s infliximab switching study tell us about the safety of switching patients from one biologic medicine to a biosimilar? Washington, DC; September 2016.
13. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., Dijkmans B.A., Tak P.P., Wolbink G.J. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010 May; 69 (5): 817-21. doi: 10.1136/ard.2009.112847.
14. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on Similar Biological Medicine Products (CHMP/437/04 Rev 1). 23 October 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. (accessed 2 Jul 2015).
15. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry. April 2015. http:// www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (accessed 2 Jul 2015).
16. Feagan B.G., Choquette D., Ghosh S., et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014; 42: 177-83.
17. Федеральный закон от 12.04.2010 N 61-ФЗ (ред. от 03.07.2016) «Об обращении лекарственных средств» (с изм. и доп., вступ. в силу с 01.01.2017).
18. Колбин А.С., Бурбелло А.Т., Загородникова К.А. Фармаконадзор в Российской Федерации и в объединённой Европе в свете новой директивы Евросоюза. Ждут ли нас изменения? Ремедиум. 2012; 8 (186): 8-14.
19. Ebbers H.C., Al-Temimi E., Moors E.H., et al. Differences Between Post-Authorization Adverse Drug Reactions of Biopharmaceuticals and Small Molecules. BioDrugs. 2013; 27 (2): 167-74.
20. Chatzantoni K., Mouzaki A. Anti-TNF-? Antibody Therapies in Autoimmune Diseases. Curr Top Med Chem. 2006; 6 (16): 1707-14.
21. McCamish M., Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012; 91: 405-17.
22. Wendling, D., Joshi, A., Reilly, P. et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014; 30: 2515-2521.
23. Raychaudhuri, S.P. and Raychaudhuri, S.K. Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases. Indian J Dermatol. 2009; 54: 100-109.
24. Lapadula, G., Marchesoni, A., Armuzzi, A. et al. Adalimumab in the treatment of immune-mediated diseases. Int J Immunopathol Pharmacol. 2014; 27: 33-48.
25. Jacobs P., Bissonnette R., Guenther L.C. Socioeconomic burden of immune-mediated inflammatory diseases-focusing on work productivity and disability. J RheumatolSuppl. 2011; 88: 55-61.
26. Gunnarsson C., Chen J., Rizzo J.A., et al. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci. 2012; 57 (12): 3080-3091.
27. Zhu, B., Edson-Heredia, E., Gatz J.L. et al. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.Clin Ther. 2013; 35: 1376-1385.
28. Yu, A.P., Tang, J., Xie, J. et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin. 2009; 25: 2429-2438.
29. American Autoimmune Related Diseases and National Coalition of Autoimmune Patient Groups. The Cost Burden of Autoimmune Diseases. 2011; http:// www.diabetesed.net/page/_files/autoimmune-diseases.pdf. Accessed July 25, 2016.
30. Villeneuve E., Haraoui B. To switch or to change class-the biologic dilemma in rheumatoid arthritis. Nat. Rev. Rheumatol. 200; 6(5): 301-305.
31. EuropaBio. Guide to biological medicines: a focus on biosimilar medicines. http://www.europabio.org/sites/default/files/report/guide_to_biological_ medicines_a_focus_on_biosimilar_medicines.pdf. Accessed August 4, 2015.
32. Boven K., Stryker S., Knight J., et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005; 67 (6): 2346-2353.
33. AbbVie. Humira (adalimumab) [prescribing information]. 2002. http://www.rxabbvie.com/pdf/humira.pdf. Accessed July 25, 2016.
34. Janssen. Remicade (infliximab) [prescribing information]. 1998. https://www.remicade.com/shared/product/remicade/prescribing-information.pdf. Accessed July 25, 2016.
35. Amgen. Enbrel (etanercept) [prescribing information]. 1998. http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf. AccessedJuly 25, 2016.
36. UCB. Cimzia (certolizumab pegol) [prescribing information]. 2008. http://www.ucb-usa.com/_up/ucb_usa_com/documents/Prescribing_Information.pdf. Accessed July 25, 2016.
37. Janssen. Simponi (golimumab) [prescribing information]. 2009. http://www.simponi.com/shared/product/simponi/prescribing-information.pdf. Accessed July 25, 2016.
38. St Clair E.W., van der Heijde D.M., Smolen J.S. et al.; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004; 50 (11): 3432-3443.
39. Singh J.A., Christensen R., Wells G.A. et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst. Rev. 2009; 4: CD007848.
40. Rubbert -Roth A., Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res. Ther. 2009; 11 (Suppl. 1): S1.
41. Billiet T., Rutgeerts P., Ferrante M., Van Assche G., Vermeire S. Targeting TNF-alpha for the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2014; 14: 75e101.
42. Willrich M.A., Murray D.L., Snyder M.R. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res 2015; 165: 270-82.
43. Насонов Е.Л. Достижения ревматологии в XXI в. Научно-практическая ревматология. 2014; 52 (2): 133-140.
44. Furst D.E., Keystone E.C., Fleischmann R. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann. Rheum. Dis. 2010; 69 (Suppl. 1): i2-i29.
45. Rendas-Baum R., Wallenstein G.V., Koncz T. et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-? inhibitors. Arthritis Res. Ther. 2011; 13 (1): R25.
46. Smolen J.S., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Ann Rheum Dis 2013;0:1 -18. doi:10.1136/annrheumdis-2013-204573.
47. Gibofsky A., Skup M., Johnson S., Chao J., Rubin D. Analysis of Outcomes After Non-Medical Switching of Anti-Tumor Necrosis Factor Agents. Ann. Rheum Dis 2015;74:701doi:10.1136/annrheumdis-2015-eular.1166.
48. Vanderpuye-Orgle J., Zhao Y., Lu J., et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015; 72 (6): 961-967.e5.
49. Wolf D.C., Skup M., Yang H., Faust E., Griffith J., Chao J., Lebwohl M. Outcomes Associated with Non-Medical Switching/Discontinuation of Anti-TNF Inhibitors Among Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). http://acrabstracts.org/abstract/outcomes-associated-with-non-medical-switchingdiscontinuation-of-anti-tnf-inhibitors-among-patients-with-rheumatoid-arthritis/. Accessed October 31, 2016.
50. Van Gestel A.M., Prevoo M.L., van’t Hof M.A. et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthr Rheum 1996; 39: 34-40.
51. Vivian P. Bykerk, Elena M. Massarotti The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology (Oxford). 2012; 51 (Suppl. 6): vi16-vi20. DOI: https://doi.org/10.1093/rheumatology/kes281.
52. Hyrich K.L., Lunt M., Dixon W.G., Watson K.D., Symmons D.P M. and on behalf of the BSR Biologics RegisterEffects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford). 2008 Jul; 47(7): 1000-1005.Published online 2008 Apr 17. doi: 10.1093/rheumatology/ken127.
53. Laas K., Peltomaa R., Kautiainen H., Leirisalo-Repo M. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin. Rheumatol. 2008; 27 (7): 927-932.
54. David T. Rubin, Martha Skup, Scott J. Johnson, Jingdong Chao, Allan Gibofsky. Analysis of Outcomes After Non-Medical Switching of Anti-Tumor Necrosis Factor Agents. 10th Congress of European Crohn’s and Colitis Organisation (ECCO), 18-21 February 2015, Barcelona, Spain.
55. Yifei Liu, Martha Skup, Jay Lin, Jingdong Chao. Impact of nonmedical switching on health care costs: A claims database analysis. Presented at ISPOR’s 20th Annual International Meeting, May 16-20, 2015.
56. Wolf D., Skup M., Yang H., Fang A.P, Kageleiry A., Chao J., Mittal M., Lebwohl M. Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons. Clin Ther. 2017 Mar 28. pii: S0149-2918(17)30179-0. doi: 10.1016/j.clinthera.2017.03.005.
Review
For citations:
Gushchina U.S., Zyryanov S.K., Orlikhina I.A. Clinical and pharmacoeconomic aspects of anti-TNF therapy change for medical reasons. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2017;(2):35-42. (In Russ.)
Views:
1442
Email this article 